NewAmsterdam Pharma Co N.V. SEC filings NAMSW
NewAmsterdam Pharma Co N.V. has 415 filings in SEC EDGAR's recent list, going back to Aug 4, 2022. Its latest annual report, Form ARS, was filed on May 6, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| S-8 | Employee stock plan registration | Jun 5, 2026 | — |
| S-8 | Employee stock plan registration | Feb 18, 2026 | — |
| 424B3 | Prospectus | Mar 10, 2025 | — |
| S-3 | Shelf registration | Feb 28, 2025 | — |
| S-8 | Employee stock plan registration | Jan 7, 2025 | — |
| 424B5 | Prospectus supplement | Dec 13, 2024 | — |
| S-3MEF | Filing | Dec 11, 2024 | — |
| 424B5 | Prospectus supplement | Dec 10, 2024 | — |
| POS AM | Filing | Aug 9, 2024 | — |
| 424B5 | Prospectus supplement | Aug 9, 2024 | — |
| S-8 | Employee stock plan registration | Jul 3, 2024 | — |
| S-3 | Shelf registration | Jul 3, 2024 | — |
| 424B3 | Prospectus | Apr 19, 2024 | — |
| POS AM | Filing | Apr 12, 2024 | — |
| 424B3 | Prospectus | Mar 12, 2024 | — |
| POS AM | Filing | Feb 28, 2024 | — |
| 424B5 | Prospectus supplement | Feb 15, 2024 | — |
| 424B5 | Prospectus supplement | Feb 13, 2024 | — |
| 424B3 | Prospectus | Dec 19, 2023 | — |
| F-3 | Shelf registration (foreign issuer) | Dec 7, 2023 | — |
| 424B3 | Prospectus | Nov 13, 2023 | — |
| 424B3 | Prospectus | Sep 21, 2023 | — |
| 424B3 | Prospectus | Aug 15, 2023 | — |
| POS AM | Filing | Aug 7, 2023 | — |
| 424B3 | Prospectus | Jun 21, 2023 | — |
| 424B3 | Prospectus | Jun 12, 2023 | — |
| 424B3 | Prospectus | Jun 8, 2023 | — |
| 424B3 | Prospectus | Jun 6, 2023 | — |
| 424B3 | Prospectus | May 23, 2023 | — |
| 424B3 | Prospectus | May 8, 2023 | — |
| 424B3 | Prospectus | Apr 25, 2023 | — |
| POS AM | Filing | Apr 17, 2023 | — |
| S-8 | Employee stock plan registration | Mar 31, 2023 | — |
| 424B3 | Prospectus | Jan 31, 2023 | — |
| F-1/A | Filing | Jan 17, 2023 | — |
| F-1 | Registration statement (foreign issuer) | Dec 20, 2022 | — |
| 424B3 | Prospectus | Oct 18, 2022 | — |
| F-4/A | Filing | Oct 13, 2022 | — |
| F-4/A | Filing | Oct 3, 2022 | — |
| F-4/A | Filing | Sep 13, 2022 | — |
| F-4 | Form f-4 | Aug 4, 2022 | — |
Showing 41 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NAMS (Nasdaq), NAMSW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Netherlands
- Headquarters
- Narrden, Netherlands
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1936258
- Former names
- NewAmsterdam Pharma Co B.V. (until Nov 22, 2022)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.